Skip to main content
. 2017 Aug 22;5(3):E653–E661. doi: 10.9778/cmajo.20170042

Table 1: Base-case cost-effectiveness results.

Intervention Cost, $ No. of life-years No. of QALYs Incremental $/life-year gained Incremental $/QALY gained
PIAAF-Pharmacy screening 443.99 9.027 6.880
No screening 417.93 9.023 6.876
Incremental 26.06 0.0032 0.0035 8213 7480

Note: PIAAF-Pharmacy = Program for the Identification of 'Actionable' Atrial Fibrillation in the Pharmacy Setting, QALY = quality-adjusted life-year.